CHAMP: Study of NVK-002 in Children With Myopia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
Stage 1: To evaluate the safety and efficacy of 2 concentrations of NVK-002 compared to Vehicle (placebo) for slowing the progression of myopia in children over a 3 year treatment period. Stage 2: To observe safety and efficacy in subjects re-randomized to one (1) year of treatment with NVK-002 or Vehicle following 3 years of treatment in children with progressive myopia.
Epistemonikos ID: e53926ff73c89c64ffb6f80d7888f4efd2ff66d0
First added on: May 21, 2024